Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency (CAPSTONE)

协调 ARDS、肺炎和败血症支持培训、组织和网络效率 (CAPSTONE)

基本信息

  • 批准号:
    10647455
  • 负责人:
  • 金额:
    $ 228.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2029-04-30
  • 项目状态:
    未结题

项目摘要

The ARDS, Pneumonia, and Sepsis (APS) Coordinating Center will support a highly functional and integrated clinical and translational research infrastructure that will enhance the quality and scientific rigor of the research conducted by the APS Phenotyping Consortium. We are a team composed of leading content and methods experts at Vanderbilt, Johns Hopkins, and University of California San Francisco. We will provide Coordination for ARDS, Pneumonia, and Sepsis supporting Training, Organization and Network Efficiency: ‘CAPSTONE’. We will support the clinical centers (CCs) in enrolling and sustaining a diverse cohort; enable the efficient and standardized capture of multi-modal cohort data with repeated measurements; model the data to understand mechanistic underpinnings of APS, including the interplay of underlying and static risk factors; and segment the population into similar prognostic and predictive phenotypes. This will enable scientific progress towards a deeper mechanistic understanding of critical illness syndromes and recovery. Functionally, we will 1) Implement the study design, data capture, and statistical analysis unit. Coordinate protocol development; establish a REDCap-based data collection, management, and security framework; conduct and support analyses; generate reports; make curated data widely available for research through a facilitated storefront; 2) Implement the clinical research management unit. Maintain cohort integrity and adherence to the protocol and manual of operations, perform routine monitoring of data quality and site performance; training of study staff; image and biospecimen management. Support site communications; facilitate recruitment and retention; and 3) Implement the stakeholder engagement and development unit. Establish bidirectional, longitudinal engagement from diverse communities; help CCs build and sustain trust; ensure strengths of each CC are nurtured and shared; facilitate dissemination of findings; support skills and career development among research teams. Our efforts will expand foundational work on APS phenotyping, identify gaps, and help create methods for redefining critical illness syndromes with the ultimate goal of improving and personalizing management strategies that will curtail the devastating morbidity and mortality caused by APS.
ARDS、肺炎和脓毒症(APS)协调中心将支持一个高度功能化的 以及整合的临床和转化研究基础设施,这将提高质量, APS表型鉴定联盟进行的研究的科学严谨性。我们是一个团队 由范德比尔特、约翰霍普金斯和大学的主要内容和方法专家组成 位于加州旧金山弗朗西斯科。我们将为ARDS、肺炎和脓毒症提供协调服务 支持培训、组织和网络效率:“CAPSTONE”。我们将支持 临床中心(CC)在招募和维持多样化队列方面的作用; 标准化采集具有重复测量的多模态队列数据;对数据进行建模, 了解APS的机制基础,包括潜在风险和静态风险的相互作用 因素;并将人群划分为相似的预后和预测表型。这将 使科学进步能够更深入地了解危重疾病的机制 症状和恢复。在功能上,我们将1)实施研究设计、数据采集和 统计分析股。协调方案制定;建立基于REDCap的数据 收集、管理和安全框架;进行和支持分析;生成 报告;通过便利的店面使策展数据广泛用于研究; 2) 实施临床研究管理单元。保持队列完整性并遵守 方案和操作手册,对数据质量和研究中心进行例行监测 性能;研究人员培训;图像和生物标本管理。支持站点 沟通;促进招聘和保留;以及3)实施利益攸关方 参与和发展股。建立双向、纵向的参与, 社区;帮助CC建立和维持信任;确保每个CC的优势得到培养, 分享;促进传播调查结果;支持技能和职业发展, 研究团队。我们的努力将扩大APS表型的基础工作,确定差距, 并帮助创建重新定义危重病综合征的方法,最终目标是 改善和个性化的管理策略,将减少毁灭性的发病率, APS引起的死亡率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gordon R Bernard其他文献

Gordon R Bernard的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gordon R Bernard', 18)}}的其他基金

ComPASS Collective for Community Engagement (C3E)
ComPASS 社区参与集体 (C3E)
  • 批准号:
    10903370
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Engaging Cooperative Sites for Trial Acceleration, Trust, Innovation, and Capability (ECSTATIC)
与试验加速、信任、创新和能力合作站点合作 (ECSTATIC)
  • 批准号:
    10650682
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
  • 批准号:
    10398799
  • 财政年份:
    2021
  • 资助金额:
    $ 228.71万
  • 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
  • 批准号:
    10609049
  • 财政年份:
    2021
  • 资助金额:
    $ 228.71万
  • 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
  • 批准号:
    10084583
  • 财政年份:
    2021
  • 资助金额:
    $ 228.71万
  • 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasma
范德比尔特临床和转化研究所 (VICTR) - 识别 SARS-CoV-2 恢复期血浆中功能免疫的相关性
  • 批准号:
    10254565
  • 财政年份:
    2020
  • 资助金额:
    $ 228.71万
  • 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
  • 批准号:
    10170009
  • 财政年份:
    2020
  • 资助金额:
    $ 228.71万
  • 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
  • 批准号:
    9490464
  • 财政年份:
    2017
  • 资助金额:
    $ 228.71万
  • 项目类别:
Vanderbilt Institute for Clinical and Translational Research (VICTR)
范德比尔特临床与转化研究所 (VICTR)
  • 批准号:
    9414517
  • 财政年份:
    2017
  • 资助金额:
    $ 228.71万
  • 项目类别:
Passive Immunity Trial for Our Neighbors (PassITON): A randomized, placebo-controlled multi-site trial of anti-SARS-CoV-2 convalescent plasma to treat hospitalized adults with COVID-19
为我们的邻居进行的被动免疫试验 (PassITON):一项随机、安慰剂对照的多中心抗 SARS-CoV-2 恢复期血浆试验,用于治疗患有 COVID-19 的住院成人
  • 批准号:
    10218949
  • 财政年份:
    2017
  • 资助金额:
    $ 228.71万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 228.71万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了